[Expert consensus on the diagnosis and treatment of non-Hodgkin lymphoma in children and adolescents (2026 edition)].

Non-Hodgkin lymphoma (NHL) is a common malignant tumor in children, accounting for approximately 7% of all childhood malignancies, with a higher incidence rate among adolescents. After standardized treatment, the overall survival rate exceeds 80%. Lymphoblastic lymphoma (LBL), mature B-cell non-Hodgkin lymphoma (mB-NHL), and anaplastic large cell lymphoma (ALCL) account for 90% of pediatric and adolescent NHL cases. The Lymphoma Group of the Oncology Branch of the Chinese Medical Association has organized multidisciplinary experts from pediatric oncology, pediatrics, internal medicine, pathology, and radiology. Based on domestic and international evidence-based evidence and extensive clinical experience, this consensus has been developed focusing on NHL common in children and adolescents (including LBL, mB-NHL, and ALCL), covering clinical manifestations, auxiliary examinations, pathological diagnosis, clinical staging, and treatment. It aims to provide evidence-based guidance for standardized clinical practice and further improve patient survival rates.